跳至主要内容
临床试验/CTIS2023-504755-26-00
CTIS2023-504755-26-00进行中(未招募)1 期

Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis (ANTEIPA) - ANTEIPA

Centre Hospitalier Intercommunal Creteil0 个研究点目标入组 196 人开始时间: 2023年11月14日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
196

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • =18 years of age, Diagnosis of bronchiectasis on thoracic CT-scan, Recent isolation of P. aeruginosa (PA) in a respiratory sample (spontaneous or induced sputum or other lower respiratory tract sample obtained by bronchoscopy) within the last 3 months, with a PA positive respiratory sample obtained = 3 weeks before randomization, Patient either Pseudomonas naive (i.e., never previously isolated PA) or Pseudomonas free (i.e., infection-free for =1 year, proven by at least two PA negative respiratory sample during the last year), Patient affiliated with the French health care system, Able to understand and sign a written informed consent form

排除标准

  • Confirmed diagnosis of cystic fibrosis, Active cancer or haematological malignancy under active therapy, Systemic corticosteroid therapy = 20 mg/d. prednisone equivalent for a predictable duration > 4 weeks, Non-tuberculous mycobacterial infection or positive non-tuberculous mycobacterial respiratory specimen within 1 year prior to inclusion, Severe chronic renal failure defined by a creatinine clearance (Cockcroft or MDRD) = 30 mL/min/1.73m2 or chronic haemodialysis, Long-term oxygen therapy and/or noninvasive mechanical ventilation for chronic respiratory insufficiency (except continuous positive airway pressure for OSA) and/or forced expiratory volume at one second (FEV1) <25% of predicted value, Patient participating to another interventional clinical trial, Pregnancy or breastfeeding, P. aeruginosa resistant to ciprofloxacin or ceftazidime, Women of childbearing potential (following menarche and until becoming post-menopausal unless permanently sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy)) who refuse to use effective contraception (hormonal or mechanical) for 3 months and/or to undergo pregnancy tests at baseline, 1 month and 3 months after baseline, Isolation of P.Aeruginosa (PA) in a respiratory specimen (spontaneous or induced sputum or other lower respiratory tract specimen obtained by bronchoscopy) more than 3 months to 12 months prior to randomization, Severe exacerbation requiring admission to an intensive care unit (e.g. for non-invasive ventilatory support, invasive mechanical ventilation, catecholamine or any other organ supportive therapy), Acute liver failure, Prior severe reaction, hypersensitivity reaction or other contraindication to any of the treatments in study (ciprofloxacin, beta-lactam, colistimethate sodium), Prior severe bronchospasm attributed to a nebulization, Patients already receiving PA suppressive therapy with an inhaled antibiotic (long-term azithromycin therapy accepted), Prior PA-eradication antibiotic treatment (systemic antibiotic(s) active against PA for = 14 days or nebulized anti-PA antibiotic) within the last year, Antibiotic treatment active against PA (anti-PA beta-lactam antibiotic and/or FQ and/or aminoglycoside) for more than 3 days before randomisation, Protected person (pregnant woman, nursing mother, person under guardianship, minor, person deprived of liberty, person unable to give consent), Patient who has already taken part in the ANTEIPA study

研究者

相似试验

Comparison of Two Antibiotic Regimens for the... | 临床试验